title: Serum undercarboxylated osteocalcin level increases with 48 weeks of teriparatide treatment in pre-treated elderly rheumatoid arthritis patients who use anti-resorptive drugs.
abstract: OBJECTIVE
  The serum undercarboxylated osteocalcin (ucOC) level, a biochemical bone marker of vitamin K insufficiency, is often affected by anti-osteoporosis drugs. There have been no reports regarding the relationship between ucOC and teriparatide.
  
  
  METHODS
  We conducted a prospective observational study of 26 female rheumatoid arthritis (RA) patients. The patients were divided into 3 groups: those who underwent a direct switch from anti-resorptive drugs to teriparatide (12 cases), those who started teriparatide without pre-treatment (5 cases), and the control patients (9 cases). The median age (interquartile range) of the patients in each group was 75 (67-77), 82 (78-84), and 69 (62-80) yr, respectively. All patients, except controls, received 48-week treatments of teriparatide. We analyzed the median 48-week changes from baseline of the serum ucOC levels with the Steel-Dwass method.
  
  
  RESULTS
  The median change from baseline in the direct switch group was higher than that in other groups (p<0.05).
  
  
  CONCLUSIONS
  The serum ucOC levels increased with treatment of teriparatide in elderly RA patients, especially when the patients received pre-treatment.
authors.affiliation: Department of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama City, Ehime, Japan. bachblau_since2001@yahoo.co.jp
authors.forename: S
authors.initials: S
authors.lastname: Mokuda
authors.forename: N
authors.initials: N
authors.lastname: Sawada
authors.forename: K
authors.initials: K
authors.lastname: Matoba
authors.forename: A
authors.initials: A
authors.lastname: Yamada
authors.forename: M
authors.initials: M
authors.lastname: Onishi
authors.forename: Y
authors.initials: Y
authors.lastname: Okuda
authors.forename: K
authors.initials: K
authors.lastname: Jouyama
authors.forename: Y
authors.initials: Y
authors.lastname: Murata
authors.forename: K
authors.initials: K
authors.lastname: Takasugi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D015415:Biomarkers / Q000097:blood*; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002264:Carboxylic Acids / Q000378:metabolism*; D005260:Female; D006801:Humans; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood*; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000209:etiology; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D019379:Teriparatide / Q000627:therapeutic use*; D013997:Time Factors; D014813:Vitamin K Deficiency / Q000097:blood / Q000139:chemically induced
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D002264:Carboxylic Acids; D015675:Osteocalcin; D019379:Teriparatide